KA
ALNY icon

Kerrisdale Advisers’s Alnylam Pharmaceuticals ALNY Stock Holding History

Kerrisdale Advisers’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-121,614
Closed -$3.77M – 71
2013
Q2 		$3.77M Buy
+121,614
New +$3.24M 1.74% 20

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Kerrisdale Advisers's ALNY Position: Q3 2013 in Review

Kerrisdale Advisers sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2013, closing a stake of 121,614 shares — an estimated $3.77M sold.

Kerrisdale Advisers first reported a position in ALNY in Q2 2013 and held it in 1 quarter. The position peaked at $3.77M in Q2 2013. 164 funds tracked by Wall St. Rank hold ALNY as of Q3 2013.

  • Kerrisdale Advisers reported no remaining Alnylam Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Kerrisdale Advisers sold 121,614 Alnylam Pharmaceuticals shares in Q3 2013, an estimated $3.77M.
  • Kerrisdale Advisers first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Kerrisdale Advisers's Alnylam Pharmaceuticals position peaked at $3.77M in Q2 2013.
  • 164 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2013.

Based on Kerrisdale Advisers's 13F filing for Q3 2013, filed 14 Nov 2013.